The Global Epistaxis Market is expected to grow at a CAGR of 5.4% during the forecast period (2023-2030).
Epistaxis is a common occurrence of bleeding from the tissue linings of the nose which is majorly seen in emergency departments. Most cases of epistaxis occur in children younger than ten years. The epistaxis is majorly differentiated by bleeding origination and it is classified as anterior & posterior epistaxis. Anterior epistaxis is suffering from the anterior septum, it is majorly encountered and can be cured by various medical approaches. The posterior epistaxis originates for the back of nasal passage are proved to be a severe medical condition as it leads to a large amount of blood loss. Epistaxis is most common in colder seasons and northern climates due to gradual descent in humidity levels and consequent drying of the nasal mucosa, hypertension, and nasal tumors. It is also caused due to the consumption of alcohol, drugs, and smoking
Metrics |
Details |
Market CAGR |
5.4% |
Segments Covered |
By Indication, By Treatment Type, By Device type, By Distribution Channel and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
For More Insights about the Market Request Free Sample
The rise in the prevalence of heart-related disorders is leading to hypertension and high blood pressure. It was found that hypertension is a significant cause of epistaxis, increase in patients suffering from nasal tumors of the benign and malignant type as they are prone to frequent epistaxis issues are driving the global epistaxis market.
Increase in prevalence of hypertension in pregnant women, during pregnancy the circulatory system expands to accommodate the baby.
This expansion leads to various problematic issues and nasal bleeds during pregnancy. Thus, the increase in hypertensive diseases among pregnant women additionally boosts the global epistaxis market. According to medical statistics of the World Health Organisation in 2015, approximately 289,000 cases of hypertension were recorded among pregnant.
According to Cancer Society in 2018, each year 2000 people are diagnosed with nasal cavity or paranasal sinus cancer in the United States, and 4 out of 5 diagnosed are 55 years and above.
According to the World Health Organization in 2018, approximately 40% of people worldwide are living with high blood pressure(hypertension).
Major factors hindering the global epistaxis market are the side effects such as pain, swelling, and running nose caused by the surgical procedures in the treatment of epistaxis.
Global epistaxis market is segmented by indication includes posterior epistaxis and anterior epistaxis. By treatment type includes medication and devices, the medication type includes topical vasoconstrictors, anesthetics, antibiotic ointments, and cauterizing agents and devices include nasal tampons, nasal dressing, and others.
The distribution channel includes hospitals, specialty clinics, retail pharmacies, and other distribution channels.
Epistaxis devises segment dominates the global epistaxis market due to extensive usage of devices, continuous technological advancements by manufacturers to improve the patient experience, increase in the prevalence of nasal membrane ruptures, and expected to remain high during the forecast period.
The global Epistaxis Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
North America dominates the global epistaxis market due to high healthcare expenditure by individuals, stringent government norms, increase in geriatric population, and continuous technological advancements in epistaxis devices and medication.
Increase in emergency admissions and inpatient admission regarding epistaxis are additionally contributing to the growth of the market in this region and are expected to remain high during the forecast period.
According to a study conducted by researchers at National Institute Of Health in 2018, 1-2 out of 200 emergency visits and 5% percent for inpatient care admissions are due to epistaxis in united states.
New epistaxis device launches by key players using advanced technologies to improve patients' experience are driving the global epistaxis market.
In 2016, Smith & Nephew launched epistaxis devices with RAPID RHINO technology that has a blend of carboxymethylcellulose (CMC) and exhibits self-lubricating provides gentle and even compression to the nasal area and helped in the quicker re-confirmation of the nasal anatomy.
Major market players in the epistaxis market are Medtronic, Boston Medical Products, Summit Medical, Inc., Medline, King Pharmaceuticals, Smith & Nephew, Cirondrugs, CogENT Therapeutics, and others.
$4350
$4350
$4350
$4350
$4350
$4350